PP2A Inhibitor PME-1 Drives Kinase Inhibitor Resistance in Glioma Cells
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Glioblastoma multiforme lacks effective therapy options. Although deregulated kinase pathways are drivers of malignant progression in glioblastoma multiforme, glioma cells exhibit intrinsic resistance toward many kinase inhibitors, and the molecular basis of this resistance remains poorly understood. Here, we show that overexpression of the protein phosphatase 2A (PP2A) inhibitor protein PME-1 drives resistance of glioma cells to various multikinase inhibitors. The PME-1–elicited resistance was dependent on specific PP2A complexes and was mediated by a decrease in cytoplasmic HDAC4 activity. Importantly, both PME-1 and HDAC4 associated with human glioma progression, supporting clinical relevance of the identified mechanism. Synthetic lethality induced by both PME-1 and HDAC4 inhibition was dependent on the coexpression of proapoptotic protein BAD. Thus, PME-1–mediated PP2A inhibition is a novel mechanistic explanation for multikinase inhibitor resistance in glioma cells. Clinically, these results may inform patient stratification strategies for future clinical trials with selected kinase inhibitors in glioblastoma multiforme. Cancer Res; 76(23); 7001–11. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chemical phylogenetics of histone deacetylases
Bradner, J. E., West, N., Grachan, M. L., Greenberg, E. F., Haggarty, S. J., Warnow, T., & Mazitschek, R. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.313 · Cited by 720 · cited 1×
“…HDAC inhibitors could be used to induce synthetic lethality together with STS and its derivatives in glioma cells, we compared effects of three inhibitors, out of which both FK228 (Romidepsin), and Panobinostat inhibit HDAC4 activity in the nanomolar range, whereas SAHA does not (39,40) (Fig.”
BackgroundProtein phosphatase 2A: a target for anticancer therapy
Perrotti, D., & Neviani, P. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70558-2 · Cited by 400
Multiple pathways regulated by the tumor suppressor PP2A in transformation
Westermarck, J., & Hahn, W. C. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.02.001 · Cited by 344
Self-citationVanderMolen, K. M., McCulloch, W., Pearce, C. J., & Oberlies, N. H. (2011) · The Journal of Antibiotics · doi:10.1038/ja.2011.35 · Cited by 333
Nuclear accumulation of HDAC4 in ATM deficiency promotes neurodegeneration in ataxia telangiectasia
Li, J., Chen, J., Ricupero, C. L., Hart, R. P., Schwartz, M. S., Kusnecov, A., & Herrup, K. (2012) · Nature Medicine · doi:10.1038/nm.2709 · Cited by 210
Structural mechanism of demethylation and inactivation of protein phosphatase 2A
Xing, Y., Li, Z., Chen, Y., Stock, J. B., Jeffrey, P. D., & Shi, Y. (2008) · Cell · doi:10.1016/j.cell.2008.02.041 · Cited by 206 · cited 2×
“The endogenous PP2A inhibitor protein, protein phosphatase methylesterase 1 (PME-1) (10), regulates PP2Ac activity by demethylating the highly conserved carboxyl-terminal tail, and by directly binding to the PP2Ac catalytic site (7,11).”
BackgroundSents, W., Ivanova, E., Lambrecht, C., Haesen, D., & Janssens, V. (2013) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08579.x · Cited by 204
Ogris, E., Du, X., Nelson, K. C., Mak, E. K., Yu, X. X., Lane, W. S., & Pallas, D. C. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.20.14382 · Cited by 191 · cited 2×
“The endogenous PP2A inhibitor protein, protein phosphatase methylesterase 1 (PME-1) (10), regulates PP2Ac activity by demethylating the highly conserved carboxyl-terminal tail, and by directly binding to the PP2Ac catalytic site (7,11).”
BackgroundMielcarek, M., Landles, C., Weiss, A., Bradaia, A., Seredenina, T., Inuabasi, L., Osborne, G. F., Wadel, K., Touller, C., Butler, R., et al. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001717 · Cited by 172
Khanna, A., Pimanda, J. E., & Westermarck, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1994 · Cited by 154 · cited 1×
“Notably, neither depletion of another PP2A inhibitor protein CIP2A (31), nor chemical compounds previously used to reactivate PP2A in cancer cells (32), induced significant synthetic lethality (Fig.”
BackgroundSelf-citation
Cited by
Protein Serine/Threonine Phosphatases: Keys to Unlocking Regulators and Substrates
Brautigan, D. L., & Shenolikar, S. (2018) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-062917-012332 · Cited by 191
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells
Kauko, O., O’Connor, C. M., Kulesskiy, E., Sangodkar, J., Aakula, A., Izadmehr, S., Yetukuri, L., Yadav, B., Padzik, A., Laajala, T. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aaq1093 · Cited by 149
“Whereas PPP2R1A depletion models cells with persistent PP2A inhibition (12), depletion of PP2A inhibitors CIP2A and PME-1 results in cells with tonally high PP2A activity (15, 20).”
BackgroundSelf-citationNon-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer
Kauko, O., & Westermarck, J. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.01.005 · Cited by 111
Self-citationMeeusen, B., & Janssens, V. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.10.002 · Cited by 96
“Overexpression of PME-1 in glioma drives resistance to various multikinase inhibitors, associated with decreased cytoplasmic activity of HDAC4 (625).”
BackgroundKauko, O., Imanishi, S. Y., Kulesskiy, E., Yetukuri, L., Laajala, T. D., Sharma, M., Pavic, K., Aakula, A., Rupp, C., Jumppanen, M., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011265 · Cited by 65
“However, despite their differential mode of PP2A regulation, the cancer-relevant phenotypes resulting from CIP2A, PME-1, or SET modulation can all be rescued by concomitant PP2A inhibition (5, 11, 29, 30).”
BackgroundResultInfluentialSelf-citation
Metadata
- Authors
- Kaur, A., Denisova, O. V., Qiao, X., Jumppanen, M., Peuhu, E., Ahmed, S. U., Raheem, O., Haapasalo, H., Eriksson, J., Chalmers, A. J., Laakkonen, P., & Westermarck, J.
- Venue
- Cancer Research
- Published
- 2016-11-30
- Volume
- 76
- Issue
- 23
- Pages
- 7001-7011
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2527130531
- Cited by
- 47
- References
- 11
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PP2A Inhibitor PME-1 Drives Kinase Inhibitor Resistance in Glioma Cells. https://app.cochat.ai/papers/10.1158/0008-5472.can-16-1134
- The paper
- Kaur, A., Denisova, O. V., Qiao, X., Jumppanen, M., Peuhu, E., Ahmed, S. U., Raheem, O., Haapasalo, H., Eriksson, J., Chalmers, A. J., Laakkonen, P., & Westermarck, J. (2016). PP2A Inhibitor PME-1 Drives Kinase Inhibitor Resistance in Glioma Cells. Cancer Research. https://doi.org/10.1158/0008-5472.can-16-1134
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.